Clinical Trends for March 2017

Ryan Syrek


March 31, 2017

Each week, we identify one top search term, speculate as to what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, feel free to share them with us on Twitter or Facebook!

Clinical Trend of the Week (March 25-31): Evolocumab

Long-awaited outcomes resulted in this week's top search term. The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial results concluded that, in addition to significantly lowering levels of low-density lipoprotein C (LDL-C), evolocumab decreased major cardiovascular events risk. The study involved more than 27,000 individuals and found a 15% reduced risk for the composite of myocardial infarction, cardiovascular death, coronary revascularization, and unstable angina hospitalization at 22 months, compared with those receiving placebo. The results indicated a 20% risk reduction for the evolocumab group for a key secondary end point, which was myocardial infarction, stroke, or cardiovascular death. These promising findings are gathering plenty of attention, including concerns about costs and guideline changes. The search term is likely to stay popular as more information becomes available.

For more information on coronary artery atherosclerosis, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.